tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Hemolysis D006461 131 associated lipids
Uremia D014511 33 associated lipids
Colitis, Ulcerative D003093 24 associated lipids
Stomach Ulcer D013276 75 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Nocardia Infections D009617 6 associated lipids
Diarrhea D003967 32 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Graft Occlusion, Vascular D006083 11 associated lipids
Hypercalcemia D006934 13 associated lipids
Neovascularization, Pathologic D009389 39 associated lipids
Adenocarcinoma D000230 166 associated lipids
Dermatitis, Contact D003877 59 associated lipids
Bacterial Infections D001424 21 associated lipids
Pain D010146 64 associated lipids
Autoimmune Diseases D001327 27 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Genital Diseases, Female D005831 7 associated lipids
Mouth Diseases D009059 5 associated lipids
Meningococcal Infections D008589 3 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Neylan JF et al. Assessment of the frequency and costs of posttransplantation hospitalizations in patients receiving tacrolimus versus cyclosporine. 1998 Am. J. Kidney Dis. pmid:9820446
Igarashi K et al. A novel indication of the activities of small molecule inhibitors of protein-protein interactions: application of the yeast two-hybrid system. 1998 J. Antibiot. pmid:9820241
Campo JV et al. Tacrolimus toxic reaction associated with the use of nefazodone: paroxetine as an alternative agent. 1998 Arch. Gen. Psychiatry pmid:9819077
Perego C et al. Evidence that SMS 201-995 enhances the immunosuppressive effect of FK506. 1998 Int. J. Immunopharmacol. pmid:9818792
Ader JL and Rostaing L Cyclosporin nephrotoxicity: pathophysiology and comparison with FK-506. 1998 Curr. Opin. Nephrol. Hypertens. pmid:9818201
Wells WA Coming full circle. Vertex Pharmaceuticals, Inc. 1998 Chem. Biol. pmid:9818152
Shapiro R et al. A prospective, randomized trial to compare tacrolimus and prednisone with and without mycophenolate mofetil in patients undergoing renal transplantation: first report. 1998 J. Urol. pmid:9817305
Bachinger A et al. [Immunosuppression with tacrolimus (FK 506) and cyclosporin A for preventing graft rejection after liver transplantation. Retrospective evaluation of medical costs based on the FG-O157 Study in 224 patients (Germany)]. 1998 Chirurg pmid:9816454
Walder B et al. Tacrolimus (FK 506)-induced hemolytic uremic syndrome after heart transplantation. 1998 J. Heart Lung Transplant. pmid:9811409
Marton MJ et al. Drug target validation and identification of secondary drug target effects using DNA microarrays. 1998 Nat. Med. pmid:9809554
Krähenbühl S et al. Serious interaction between mibefradil and tacrolimus. 1998 Transplantation pmid:9808502
Nakazawa Y et al. Relationship between in vivo FK506 clearance and in vitro 13-demethylation activity in living-related liver transplantation. 1998 Transplantation pmid:9808496
Cacciarelli TV et al. Management of posttransplant lymphoproliferative disease in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy. 1998 Transplantation pmid:9808490
Hultsch T et al. Ascomycin macrolactam derivative SDZ ASM 981 inhibits the release of granule-associated mediators and of newly synthesized cytokines in RBL 2H3 mast cells in an immunophilin-dependent manner. 1998 Arch. Dermatol. Res. pmid:9808344
Cardenas ME et al. Signal-transduction cascades as targets for therapeutic intervention by natural products. 1998 Trends Biotechnol. pmid:9807840
Faure JD et al. An Arabidopsis immunophilin, AtFKBP12, binds to AtFIP37 (FKBP interacting protein) in an interaction that is disrupted by FK506. 1998 Plant J. pmid:9807817
Boguniewicz M et al. A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. Pediatric Tacrolimus Study Group. 1998 J. Allergy Clin. Immunol. pmid:9802373
Bieber T Topical tacrolimus (FK 506): a new milestone in the management of atopic dermatitis. 1998 J. Allergy Clin. Immunol. pmid:9802361
Reis A et al. A comparative investigation of FK506 and cyclosporin A in murine corneal transplantation. 1998 Graefes Arch. Clin. Exp. Ophthalmol. pmid:9801895
Conti F et al. Low level of interleukin 10 synthesis during liver allograft rejection. 1998 Lab. Invest. pmid:9800954